Senti Biosciences Inc SNTI

Healthcare Biotechnology

Senti Biosciences, Inc. is a clinical-stage biotechnology company. It is developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. It is focused on off-the-shelf CAR-NK cell therapy programs for oncology indications. Its lead product candidate, SENTI-202, is a potential Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia, while sparing healthy bone marrow cells. Its second clinical development program is SENTI-301A, a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy. SENTI-202 has been designed to incorporate three chimeric proteins using a Logic Gated gene circuit and delivered through a single retrovirus. SENTI-301A is a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy designed for the treatment of advanced GPC3 positive tumors.

NDAQ:SNTI - Post by User

Senti Biosciences Inc

<< Previous

Bullboard Posts

Next >>

Post by SkyProfit12on Dec 04, 2024 9:01am

26 Views

Post# 36344781

$SNTI Slips, $MYNZ Builds for the Future

$SNTI falls 29% to $7.14 amid concerns in synthetic biology progress. Meanwhile, $MYNZ, post-reverse split, is regaining strength, advancing its focus on molecular diagnostics and showing promise for long-term growth in the biotech space.

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features